Literature DB >> 10469430

Epidemiology of neurofibromatosis type 1.

J M Friedman1.   

Abstract

The prevalence of neurofibromatosis type 1 (NF1) is about 1/3,000. There are no known ethnic groups in which NF1 does not occur or is unusually common. The prevalence is somewhat higher in young children than in adults, a difference that probably results at least in part from the early death of some NF1 patients. NF1 is fully penetrant in adults, but many disease features increase in frequency or severity with age. The reproductive fitness of NF1 patients is reduced by about one-half. About half of all cases result from new mutations. The estimated rate of new NF1 mutations is unusually high, but the basis for this high mutation rate is not known. Am. J. Med. Genet. (Semin. Med. Genet.) 89:1-6, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10469430

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  138 in total

1.  Are rare variants responsible for susceptibility to complex diseases?

Authors:  J K Pritchard
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

Review 2.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 3.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

4.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

Authors:  Weixi Wang; Jeffry S Nyman; Koichiro Ono; David A Stevenson; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2011-07-14       Impact factor: 6.150

5.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

6.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

7.  Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.

Authors:  Xiaodong Zhou; Sung-Hoon Kim; Ling Shen; Hyo-Jung Lee; Changyan Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 8.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

Review 9.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

10.  Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Authors:  Christine M Kivlin; Kelsey L Watson; Ghadah A Al Sannaa; Roman Belousov; Davis R Ingram; Kai-Lieh Huang; Caitlin D May; Svetlana Bolshakov; Sharon M Landers; Azad Abul Kalam; John M Slopis; Ian E McCutcheon; Raphael E Pollock; Dina Lev; Alexander J Lazar; Keila E Torres
Journal:  Cancer Biol Ther       Date:  2015-12-09       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.